Thu, Jul 31, 2014, 3:31 AM EDT - U.S. Markets open in 5 hrs 59 mins

Recent

% | $
Click the to save as a favorite.

MannKind Corp. Message Board

thekindaguyiyam 20 posts  |  Last Activity: Jul 26, 2014 3:33 PM Member since: Jun 7, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    A note to Al Mann

    by pokeysun Jul 26, 2014 12:09 PM
    thekindaguyiyam thekindaguyiyam Jul 26, 2014 3:33 PM Flag

    most people still have no clue what technosphere is and the patents approved for it's "revolutionary" delivery. system (FDA) The shorts what you to think that Afrezza is Exubra. It is not. 1/3 of the worlds population are diabetic or pre diabetic. Next technospere drug delivery for pain; a bigger market than for diabetes.
    ALFRED MANN is a the Tesla in our lifetime.

    Sentiment: Strong Buy

  • Reply to

    Dead Money In A Raging Bull Market

    by jewhader3 Jul 16, 2014 10:49 AM
    thekindaguyiyam thekindaguyiyam Jul 16, 2014 11:00 AM Flag

    your name says it all. You are a sick #$%$. I have no room for nazis in my world. Goodbye forever. IggyZone for you and your puny little mind.

    Sentiment: Strong Buy

  • Reply to

    Guess I was wrong

    by stockwatcher7504 Jul 16, 2014 9:40 AM
    thekindaguyiyam thekindaguyiyam Jul 16, 2014 10:56 AM Flag

    your lack of patience is based in lack of confidence that your expectations didn't manifest in your own subjective time frame. ADA overwhelmingly positive. FDA approval weeks before deadline. Shares have dried up. Alfred Mann's Namesake company is on the edge of announcement. And you; either a fool, afraid and or have alternative motives because of life not going exactly as you planned. Now; that's just stupid; cause life rarely delivers exactly what we want in the time frame we want it. If you don't have the patience then you might want to invest in typewriters. I'm not here to hold your hand. I'm here to make money on a delivery system called technospere that will deliver an inhaled ultra fast insulin that will provide comfort, and improvement in the lives of 1/3 of the worlds population. Since I spend my time on worthy posts and read endlessly on a daily bases for my affirmation in my investments; it's clear to me that what you offer doesn't add to my knowledge base. Therefore; off you go to the Iggy Zone. Enjoy!

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jul 11, 2014 10:43 PM Flag

    tell em what they want; but, technospere is not for sale. Afrezza is. Dreamboat deliver's the first technosphere delivery of the 1st of hundreds of patents. All of those patents and the "revolutionary new delivery system" is not for sale. I am long holding many shares and calls. You may think you know what the company is going to do; but from my perspective your have it wrong. Afrezza will be partnered. MNKD will continue to manufacture it in Danbury but the marketing will be a partnership with a global pharm. The next drug out using the technosphere delivery after afrezza's proven success will be a drug next spring for people with chronic pain which is 4X the population of Diabetes. My friend; you have to do more research... technosphere is a diamond mine that is not for sale. If you can prove otherwise; I'd be happy to acknowledge your subjective allegation.

    Sentiment: Strong Buy

  • NEW YORK (AVAFIN) -- Options traders were heavily trading call contracts during the last trading session establishing a new 3-month call volume record. A total of 5,777 put and 17,481 calls were traded where call contracts outnumbered puts 3.0:1, yielding a 0.33 ratio.
    Options are useful tools for predicting the movement of the underlying stock. Put/Call ratio statistics serve as a useful predictor of investment sentiment, indicating what experienced investors are doing in preparation for a move of an underlying stock. Thus, unusual volume provides reliable clues that the stock is expected to make a move.
    Shares of MNKD closed at $10.07 during the previous session. During the session, the stock hit a low of $9.81 and high of $10.10. The current trading volume of 5.04M is less than average volume of 13.69M shares. MNKD is trading above the 50 day moving average and higher than the 200 day moving average. The stock's 52 week low is $3.80 and 52 week high is $11.48. To date, the stock has gained 0.10% within the last week.
    MannKind Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jul 6, 2014 1:15 PM Flag

    so you are saying that mankind leaked a story. no proof just pump. Friend; I am very LONG.
    What you say is true on one level. MNKD will partner up with a Global Pharmaceutical company and it is only a matter of time. This conclusion requires no genius. I hate those guys who create the FUD and I don't care for pumpers much either. Just give us provable facts; that's all what any INVESTOR wants.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jul 6, 2014 11:21 AM Flag

    yours isn't worth reading. ignore list for you; you waste our time with noise.

    Sentiment: Strong Buy

  • Reply to

    Go to Webmd and search Afrezza FAQ

    by radgray68 Jul 2, 2014 1:26 AM
    thekindaguyiyam thekindaguyiyam Jul 2, 2014 1:03 PM Flag

    June 30, 2014 -- Millions of people with type 1 or type 2 diabetes will have another treatment option now that the FDA has approved an inhaled insulin.

    Called Afrezza, the rapid-acting insulin is taken before each meal, or soon after starting to eat, with no needles required. Afrezza won't replace the need for injected long-acting insulin for those who need it, though.

    WebMD asked diabetes experts about this newest option:

    How is Afrezza different than other insulin?

    Because it's inhaled, it's absorbed more quickly and in a different way.

    "Afrezza is rapidly absorbed from the cells in the lungs [to the blood stream]," says R. Keith Campbell, RPh. He's a certified diabetes educator and distinguished professor emeritus in diabetes care and pharmacotherapy at Washington State University College of Pharmacy. He has studied the drug but has no ties to its developer.

    "From the time you inhale it to the time it actually peaks [in the blood] is 15 to 20 minutes," Campbell says. Injected insulin taken before a meal, he says, takes about an hour to peak.

    The body also clears Afrezza more quickly than insulin injected at mealtime, says Bruce Bode, MD. He's a diabetes specialist in Atlanta who did a clinical trial funded by MannKind Corporation, the drug’s developer.
    Besides its rapid peak, the drug is ''pretty much gone in 2 or 3 hours," Bode says. Rapid-acting injected insulins, he says, usually ''hang around for about 4 hours. Afrezza is fast in, fast out. It is emulating, in essence, what the pancreas does."

    How is it taken?

    Users place a dose of Afrezza, in powder form, into a small, whistle-sized inhaler. Doses come in a cartridge, and each cartridge contains a single dose.
    How does Afrezza work compared to rapid-acting injected insulins?
    In a 24-week study, Bode compared Afrezza with a rapid-acting, injected insulin in more than 500 patients with type 1 diabetes. Afrezza and injected insulin controlled blood sugar equally well, he says. continues...

    Sentiment: Strong Buy

  • Reply to

    Fullshred's post from iHub

    by yeffrey22 Jul 2, 2014 12:08 PM
    thekindaguyiyam thekindaguyiyam Jul 2, 2014 12:57 PM Flag

    good analysis of the situation. remarkable too that the shorts wildly control the price and know very little about diabetes or give a dam about the remedy assisting a huge population. To the shorts Afrezza is a commodity in which they can manipulate with the help of Cramer and his cronies to make as much money as possible. Money is the market goal. Remedy is the goal of the science of Mannkind.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jun 29, 2014 4:36 PM Flag

    Techosphere has been accepted by the FDA. Technosphere is the delivery system while DreamBoat is the disposable apparatus. Afrezza is the First Technosphere delivery. The next patent coming before the FDA is from MNKD in spring of next year for people with Chronic Pain which is a non narcotic. Population of that market is 4X's that of Afrezza's Diabetes Meds. Now add another 400 -700 patents for ultra fast delivery for many other diseases and you will get a glimpse of what Technospere from Mannkind really is; a paradigm shift for improved delivery and much much faster. Me? I'll sell when Alfred sells.

    Sentiment: Strong Buy

  • Reply to

    MNKD From "Think like a Surgeon" #1

    by thekindaguyiyam May 17, 2014 7:14 PM
    thekindaguyiyam thekindaguyiyam May 18, 2014 12:12 AM Flag

    CJ: Absolutely--it's going to be about execution. Here are the milestones: You've got the PDUFA date first, which could come earlier than July 15. I think a partnership will come around that time; maybe after the PDUFA date. The story is not about approval at this point; it is about getting a good partnership and selling the drug. What will the launch curve look like? We're modeling the launch curve beginning in 2015, and that's being conservative. Sales could come earlier. MannKind is evolving into an execution story.

    yahoo won't let me post the link. google Think Like a Brain Surgeon Dr. Christopher James Offers Fresh Exciting Biotechs

    Sentiment: Strong Buy

  • Reply to

    MNKD From "Think like a Surgeon" #1

    by thekindaguyiyam May 17, 2014 7:14 PM
    thekindaguyiyam thekindaguyiyam May 17, 2014 7:21 PM Flag

    Cotinues: Given Afrezza's attractive profile it will get wide adoption in the marketplace.
    Furthermore, the delay gives the company more time to negotiate a better label. If MannKind had only two weeks, it would have had to accept any label that the FDA threw on it. It also allows more time for negotiating on the partnership side, so that the company can reach a more favorable deal with a marketing partner. The delay, combined with the very favorable vote at the AdCom meeting, has given MannKind greater leverage for negotiation with a pharma company.
    Finally, approval can come much earlier than July 15. I doubt the FDA needs the entire 90 days to come to a decision to approve the product and figure out the final labeling. The FDA does not have unlimited manpower, and it probably wants to move on to other NDAs. I believe the FDA knows where it's going with Afrezza and would like to get this wrapped up quickly.
    TLSR: Were there issues discussed at the AdCom regarding pulmonary function and carcinogenicity?
    CJ: Those were the biggest issues discussed on the safety side--the long-term pulmonary effects on patients with asthma, chronic obstructive pulmonary disease, effects in smokers and even effects in patients who previously smoked and have quit. But carcinogenicity is definitely a theoretical effect. There were two patients that the FDA was particularly concerned with, because they developed lung cancer and were not smokers. I thought the FDA would be much more concerned and restrictive on this end but, at the end of the day, the decision was that, outside of conducting a very large, 10-year study, we just don't know if Afrezza is carcinogenic. That's going to be a post-marketing commitment at most.
    TLSR: Do you believe the FDA could exclude type 1 diabetes patients from this label?
    CJ: I think the chance of that is as close to zero as you can get.
    TLSR: Is MannKind a developing revenue story from here?

  • thekindaguyiyam by thekindaguyiyam May 17, 2014 7:14 PM Flag

    TLSR: Chris, you have MannKind Corp. (MNKD:NASDAQ) under coverage. The company has developed an inhalable insulin product called Afrezza (human insulin of recombinant DNA origin delivered via Technosphere particles). This product was overwhelmingly accepted by the FDA's Endocrinologic and Metabolic Drug Advisory Committee (AdCom) meeting on April 1; however, the FDA delayed the PDUFA date three months to July 15. Even with that surprise announcement, the stock has remained strong since the AdCom. Could you discuss this name?
    CJ: MannKind is a great example of a stock that I think investors should be currently buying. We have a $12 price target on the shares. A lot of uncertainty has been flushed out of this story with the recent AdCom meeting, which was overwhelmingly positive. You mentioned that the stock is holding up fairly well in this environment, and I would agree that folks, including myself, did not view the PDUFA extension as truly a negative event.
    Given the timing between the AdCom and the original PDUFA date, I don't think the PDUFA delay was a surprise. The original date was just two weeks after the AdCom, and I think most people on the Street felt there was a possibility that the PDUFA could be pushed out, just because of that quick timeframe. That is one reason the stock has remained strong.
    Second, I think the overwhelmingly positive AdCom vote surprised the FDA. I was at the panel, and it was very clear, within the first 30 minutes, that things were going in a positive direction--which was very different from the read I got from the briefing documents that were disseminated by the FDA a few days before the AdCom.
    I also think the FDA needs additional time to discuss all the issues on subpopulations of patients. I think that's the bear story now: that the label is going to be narrow, and that the company may not be able to sell Afrezza to a broad population of type 1 and type 2 diabetes patients. I don't feel that will be the case at all.

  • Reply to

    Did I hear correctly?

    by clevans1 May 15, 2014 8:39 PM
    thekindaguyiyam thekindaguyiyam May 15, 2014 9:15 PM Flag

    Graig Suvannavejh - MLV & Company
    "Alright. Okay. Great. So what is if there is a default plan right now, do you have one placed around ADA activities?"

    Hakan Edstrom - President, Chief Operating Officer, Director
    "Well, not specifically but I could say that the amount of money that we would spend potentially in vain for those depending on the timing of approval. We could do a lot in terms of other information needed and some other activities in conjunction with the ADA, plus the fact we may even be in a situation where we will have a partnering opportunity there if we have both the partner and the approval in place at the time. So I think we will have to be just a little bit (inaudible) and do the best we can."

    Sentiment: Strong Buy

  • Reply to

    actual shares available.

    by millsproperty May 15, 2014 4:08 PM
    thekindaguyiyam thekindaguyiyam May 15, 2014 6:08 PM Flag

    I think an announcement of some sort of partnership will be announced within 48 hours of FDA announcement. imho

    Sentiment: Strong Buy

  • Reply to

    Cramer just #$%$ on MNKD

    by cvs9yt Apr 17, 2014 7:09 PM
    thekindaguyiyam thekindaguyiyam May 13, 2014 4:40 PM Flag

    Cramer is funny... he has the Street hit Mannkind sometimes with 2 or 3 articles in a day. He has a sports journalist give a thumbs up to an idiot post of dance which is years off / requires batteries and a working motherboard; and FIVE TIMES THE SIZE of a non mechanical device with few moving parts, requires no batteries and is designed to be disposed of and replaced ever 2 weeks. Cramer doesn't know the size?!
    It's like his video when asked about MNKD he puts his hand up in the air as if he is being held up by someone with a gun and says "I have no opinion". Yeah... Cramer is quite the king of deception. When he endorses
    MNKD there is generally a bear raid using the media to create smokescreen comparisons such as the one of competion of Dance Pharma and Mannkind's Afrezza. Go figure.

    Sentiment: Strong Buy

  • Reply to

    The Money line from the conference!

    by cphammer May 13, 2014 5:51 AM
    thekindaguyiyam thekindaguyiyam May 13, 2014 4:30 PM Flag

    facts instead of B.S. ... very refreshing.

    Sentiment: Strong Buy

  • Reply to

    waiting for entry point.

    by davidthebutcher1 May 13, 2014 8:47 AM
    thekindaguyiyam thekindaguyiyam May 13, 2014 4:20 PM Flag

    your foresight is pretty screwed up. no doubt your hindsight will be better. You are IggyZone material.
    and there you go... off to ramble foolishness to those foolish enough to listen to you. See ya shortie.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam May 13, 2014 4:16 PM Flag

    here anyone can say anything. truth or dignity don't matter. these guys are playing on a board that does no human interface. It is unregulated. So any moron can have 100 ID's x 3 people and you can make up your own world and fantasy trying to manipulate emotion with one IP address. Don't expect
    "fair" as in this land there is no law and people manipulate any stock as a commodity regardless of the efficacy of the drug or the merit of the company. Iggy all the fools and your own life will be better. If you want a board overseen by people who only allow one IP address then you go to the pro boards.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam May 13, 2014 4:11 PM Flag

    What an #$%$ you are. good luck paying the rent shortie and enjoy your trip to the IggyZone

MNKD
8.660.00(0.00%)Jul 30 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.